---
title: Antibiotics - Antibacterial Agents
type: content
phase: 1
status: complete
priority: high
tags: [antibiotics, beta-lactams, penicillins, cephalosporins, carbapenems, aminoglycosides, macrolides, fluoroquinolones, tetracyclines, vancomycin, antimicrobial-resistance]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antibiotics - Antibacterial Agents

## Introduction

Antibiotics are among the most important therapeutic discoveries in medicine, dramatically reducing mortality from bacterial infections. Understanding mechanisms of action, spectrum of activity, pharmacokinetics, adverse effects, and resistance patterns is essential for rational antimicrobial prescribing.

## Core Concepts

### Bactericidal vs. Bacteriostatic

**Bactericidal**: Kill bacteria
- β-lactams, aminoglycosides, fluoroquinolones, vancomycin

**Bacteriostatic**: Inhibit bacterial growth
- Macrolides, tetracyclines, sulfonamides, linezolid

**Clinical Significance**:
- Bactericidal preferred in: Endocarditis, meningitis, neutropenic patients
- Distinction not always clinically relevant at therapeutic doses

### Mechanisms of Action

1. **Cell wall synthesis inhibition**: β-lactams, vancomycin
2. **Protein synthesis inhibition**: Aminoglycosides, macrolides, tetracyclines, linezolid
3. **DNA/RNA synthesis inhibition**: Fluoroquinolones, rifampin
4. **Folate synthesis inhibition**: Sulfonamides, trimethoprim
5. **Cell membrane disruption**: Polymyxins, daptomycin

### Antimicrobial Resistance

**Mechanisms**:
1. **Enzymatic inactivation**: β-lactamases, aminoglycoside-modifying enzymes
2. **Target modification**: Altered PBPs (MRSA), ribosomal methylation
3. **Efflux pumps**: Tetracycline, fluoroquinolone resistance
4. **Decreased permeability**: Porin mutations

**Key Resistance Patterns**:
- **MRSA**: Methicillin-resistant S. aureus (altered PBP2a)
- **VRE**: Vancomycin-resistant enterococci (altered D-Ala-D-Lac)
- **ESBL**: Extended-spectrum β-lactamases (hydrolyze 3rd gen cephalosporins)
- **CRE**: Carbapenem-resistant Enterobacteriaceae (carbapenemases)
- **MDR**: Multi-drug resistant organisms

---

## Beta-Lactam Antibiotics

### Mechanism of Action

**All β-lactams**:
- Inhibit bacterial **cell wall synthesis**
- Bind **Penicillin-Binding Proteins (PBPs)**
- Inhibit transpeptidation (cross-linking of peptidoglycan)
- Activate autolysins → cell lysis
- **Time-dependent killing** (efficacy related to time above MIC)
- **Bactericidal**

**Resistance**:
- **β-lactamases**: Enzymes that hydrolyze β-lactam ring
- **Altered PBPs**: Decreased drug binding (MRSA)
- **Efflux pumps, decreased permeability**

---

## Penicillins

### Classification

1. **Natural Penicillins**: Penicillin G, Penicillin V
2. **Antistaphylococcal**: Nafcillin, Oxacillin, Dicloxacillin
3. **Aminopenicillins**: Ampicillin, Amoxicillin
4. **Anti-Pseudomonal**: Piperacillin, Ticarcillin
5. **β-lactamase Inhibitor Combinations**

### Penicillin G and V

**Penicillin G** (IV/IM):
- **Spectrum**: Narrow
  - Streptococci (Groups A, B, viridans)
  - Syphilis (T. pallidum)
  - Actinomyces
  - Some anaerobes
- **NOT active**: Staphylococci (β-lactamase), Gram-negatives

**Formulations**:
- Aqueous penicillin G (IV): Short-acting
- Procaine penicillin G (IM): Intermediate-acting
- Benzathine penicillin G (IM): Long-acting (weeks)

**Penicillin V** (PO):
- Acid-stable (oral bioavailability)
- Same spectrum as penicillin G
- Strep pharyngitis

**Clinical Uses**:
- Streptococcal pharyngitis (Penicillin V)
- Syphilis (Benzathine Pen G IM)
- Neurosyphilis (Aqueous Pen G IV)
- Streptococcal meningitis, endocarditis
- Gas gangrene (Clostridium perfringens)

**Adverse Effects**:
- **Hypersensitivity** (1-10%):
  - Type I (IgE-mediated): Urticaria, angioedema, anaphylaxis (0.004-0.04%)
  - Type IV (delayed): Maculopapular rash
- **Cross-reactivity**: 2-5% cross-allergy with cephalosporins (low if not anaphylactic)
- **Jarisch-Herxheimer reaction**: Fever, chills after treatment of syphilis (cytokine release from dying spirochetes)
- Seizures (high doses, renal failure)
- Interstitial nephritis

### Antistaphylococcal Penicillins

**Drugs**: Nafcillin, Oxacillin, Dicloxacillin

**Mechanism**:
- β-lactamase resistant (bulky side chains)
- Bind PBPs

**Spectrum**:
- **Methicillin-sensitive S. aureus (MSSA)**
- Streptococci
- **NOT active against MRSA, Gram-negatives**

**Clinical Uses**:
- **MSSA infections** (skin/soft tissue, bacteremia, endocarditis, osteomyelitis)
- Empiric for skin infections (if MRSA risk low)

**Nafcillin**:
- IV only
- **Hepatic elimination** (safe in renal failure)
- Phlebitis common

**Oxacillin**:
- IV only
- Similar to nafcillin

**Dicloxacillin**:
- Oral
- Outpatient MSSA infections

**Adverse Effects**:
- Hypersensitivity
- Phlebitis (IV)
- Interstitial nephritis (oxacillin)
- Hepatotoxicity (rare)

### Aminopenicillins

**Drugs**: Ampicillin, Amoxicillin

**Spectrum**:
- Streptococci
- Enterococcus faecalis (E. faecium resistant)
- **Gram-negative**: E. coli, Proteus mirabilis, H. influenzae, Salmonella
- Listeria monocytogenes
- **Susceptible to β-lactamases**

**Ampicillin**:
- IV or PO (poor oral bioavailability)
- **Clinical uses**:
  - Listeria meningitis
  - Enterococcal infections (with gentamicin for synergy)
  - Community-acquired pneumonia (CAP) - less common now

**Amoxicillin**:
- **Oral** (better bioavailability than ampicillin)
- **Clinical uses**:
  - Strep pharyngitis (alternative to penicillin V)
  - Otitis media, sinusitis
  - CAP (outpatient)
  - H. pylori (triple therapy)
  - Dental prophylaxis (endocarditis prevention)

**Adverse Effects**:
- Hypersensitivity
- **Rash**: Maculopapular rash (5-10%)
  - **Nearly universal** (90%) if given during EBV mononucleosis
  - Not true allergy
- Diarrhea (common)
- C. difficile infection

### Beta-Lactamase Inhibitor Combinations

**Inhibitors**: Clavulanic acid, Sulbactam, Tazobactam, Vaborbactam, Avibactam

**Mechanism**:
- **"Suicide" inhibitors** of β-lactamases
- Bind β-lactamase → irreversible inhibition
- Restore activity against β-lactamase-producing organisms

**Combinations**:

**Amoxicillin-Clavulanate** (Augmentin):
- PO
- **Spectrum**: MSSA, streptococci, E. coli, Klebsiella, Proteus, H. influenzae, Moraxella, anaerobes
- **Clinical uses**:
  - Sinusitis, otitis media
  - Animal/human bites (Pasteurella, Eikenella)
  - CAP (outpatient)
  - Dental infections
- **Adverse effects**:
  - Diarrhea (common - clavulanate)
  - Nausea
  - Cholestatic jaundice (rare)

**Ampicillin-Sulbactam** (Unasyn):
- IV
- **Spectrum**: Similar to amoxicillin-clavulanate + Acinetobacter
- **Clinical uses**:
  - Intra-abdominal infections
  - Aspiration pneumonia
  - Skin/soft tissue infections
  - Acinetobacter (sulbactam has intrinsic activity)

**Piperacillin-Tazobactam** (Zosyn):
- IV
- **Spectrum**: Broad
  - Gram-positive: Streptococci, MSSA
  - Gram-negative: **Pseudomonas aeruginosa**, Enterobacteriaceae (including many ESBL)
  - Anaerobes: Bacteroides fragilis
- **Clinical uses**:
  - Hospital-acquired/ventilator-associated pneumonia (HAP/VAP)
  - Intra-abdominal infections
  - Neutropenic fever
  - Severe sepsis (empiric broad-spectrum)
- **Adverse effects**:
  - Hypersensitivity
  - Hypokalemia (distal tubule K+ wasting)
  - Platelet dysfunction (high doses)

**Ceftazidime-Avibactam** (Avycaz):
- IV
- **Spectrum**: Covers CRE (some carbapenemases)
- Reserved for multi-drug resistant Gram-negatives

**Meropenem-Vaborbactam** (Vabomere):
- IV
- **Spectrum**: CRE (KPC-producing)
- Reserved for carbapenem-resistant organisms

### Anti-Pseudomonal Penicillins

**Drugs**: Piperacillin, Ticarcillin (rarely used alone now; combined with β-lactamase inhibitors)

---

## Cephalosporins

### General Features

- β-lactam structure (different ring system than penicillins)
- Inhibit cell wall synthesis (bind PBPs)
- Bactericidal
- **Generally safe in penicillin allergy** (2-5% cross-reactivity if IgE-mediated)
- **Generations**: 1st through 5th (↑generation → ↑Gram-negative, ↓Gram-positive coverage generally)

### First Generation

**Drugs**: Cefazolin (IV), Cephalexin (PO)

**Spectrum**:
- **Gram-positive**: MSSA, streptococci (NOT enterococcus, NOT MRSA)
- **Gram-negative**: E. coli, Klebsiella, Proteus (PEcK)
- **NOT active**: Pseudomonas, anaerobes (Bacteroides)

**Clinical Uses**:

**Cefazolin**:
- **Surgical prophylaxis** (most common use)
- Skin/soft tissue infections (MSSA)
- UTI (E. coli, Klebsiella)

**Cephalexin**:
- Skin/soft tissue infections (MSSA) - outpatient
- UTI

### Second Generation

**Cefuroxime** (IV/PO - Ceftin), **Cefoxitin**, **Cefotetan**

**Spectrum**:
- **Expanded Gram-negative**: H. influenzae, Moraxella, Neisseria
- **Gram-positive**: Similar to 1st gen (less active vs. MSSA)

**Cefoxitin, Cefotetan** (Cephamycins):
- **Anaerobic coverage**: Bacteroides fragilis
- Intra-abdominal infections, pelvic infections

**Clinical Uses**:
- CAP (cefuroxime)
- Intra-abdominal infections (cefoxitin, cefotetan)
- Surgical prophylaxis (cefoxitin for GI/GYN surgery)

### Third Generation

**Drugs**: Ceftriaxone, Cefotaxime (IV); Cefixime, Cefpodoxime (PO); Ceftazidime (IV - anti-Pseudomonal)

**Spectrum**:
- **Excellent Gram-negative**: Enterobacteriaceae, H. influenzae, Neisseria
- **Gram-positive**: Streptococci (less active than 1st gen vs. MSSA)
- **CSF penetration**: Ceftriaxone, cefotaxime
- **Ceftazidime**: **Anti-Pseudomonal** activity

**Ceftriaxone**:
- **Long half-life** (allows once-daily dosing)
- **Biliary excretion** (safe in renal failure without dose adjustment)
- **CSF penetration**
- **Clinical uses**:
  - **Meningitis** (empiric + vancomycin)
  - **Gonorrhea** (500 mg IM × 1, now increased to 500 mg due to resistance)
  - CAP (hospitalized)
  - Pyelonephritis
  - Intra-abdominal infections (with metronidazole)
  - Lyme disease (neuroborreliosis)
  - Spontaneous bacterial peritonitis (SBP)
- **Adverse effects**:
  - **Biliary sludging/pseudolithiasis** (especially children)
  - **Do not mix with calcium** (precipitation)
  - Disulfiram-like reaction

**Cefotaxime**:
- Similar to ceftriaxone
- Shorter half-life (TID dosing)
- Preferred in neonates (no biliary issues)

**Ceftazidime**:
- **Anti-Pseudomonal**
- **Poor Gram-positive coverage**
- Clinical uses:
  - Pseudomonas infections
  - Neutropenic fever (with anti-Gram-positive agent)

**Cefixime** (PO):
- Gonorrhea (alternative)
- UTI

### Fourth Generation

**Cefepime** (IV)

**Spectrum**:
- **Broad**: Gram-positive (like 1st gen) + Gram-negative (like 3rd gen)
- **Anti-Pseudomonal**
- **More β-lactamase stable** than 3rd gen

**Clinical Uses**:
- HAP/VAP (Pseudomonas coverage)
- Neutropenic fever
- Intra-abdominal infections
- Severe sepsis (empiric)

**Adverse Effects**:
- **Neurotoxicity**: Encephalopathy, seizures (especially renal impairment)

### Fifth Generation

**Ceftaroline** (Teflaro)

**Unique Feature**:
- **Active against MRSA** (binds PBP2a)
- Also covers Gram-negatives (NOT Pseudomonas)

**Clinical Uses**:
- MRSA skin/soft tissue infections
- MRSA pneumonia (CAP)

**Limitation**:
- No anti-Pseudomonal activity

### Cephalosporin Adverse Effects (General)

- **Hypersensitivity**: Rash, urticaria, anaphylaxis (rare)
  - **Cross-reactivity with penicillins**: ~2-5% (primarily with similar R1 side chains)
- **GI upset, diarrhea**
- **C. difficile infection**
- **Disulfiram-like reaction**: Cefotetan, cefoperazone (methylthiotetrazole side chain)
- **Vitamin K deficiency/bleeding**: Cefotetan (inhibits vitamin K metabolism)
- **Seizures**: Especially cefepime in renal failure
- **Hemolytic anemia**: Ceftriaxone (rare, immune-mediated)

---

## Carbapenems

**Drugs**: Imipenem, Meropenem, Ertapenem, Doripenem

### Mechanism of Action

- β-lactam antibiotics
- Inhibit cell wall synthesis
- **Extremely β-lactamase stable**
- Bactericidal

### Spectrum

**Broadest spectrum antibiotics**:
- **Gram-positive**: MSSA, streptococci (NOT MRSA, NOT Enterococcus faecium)
- **Gram-negative**: Enterobacteriaceae (including ESBL producers), Pseudomonas (except ertapenem)
- **Anaerobes**: Bacteroides fragilis
- **Atypicals**: NOT covered

**Resistance**:
- **CRE**: Carbapenem-resistant Enterobacteriaceae (carbapenemases like KPC, NDM)
- Serious threat, limited treatment options

### Individual Agents

**Imipenem-Cilastatin**:
- **Cilastatin**: Inhibits renal dehydropeptidase-1 (prevents imipenem degradation in kidneys)
- **Seizure risk**: Highest among carbapenems
- Covers Pseudomonas

**Meropenem**:
- **Lower seizure risk** than imipenem (preferred for CNS infections)
- Covers Pseudomonas
- **Most commonly used carbapenem**

**Ertapenem**:
- **Once-daily dosing** (long half-life)
- **NO anti-Pseudomonal activity** (NOT for Pseudomonas)
- **NO Enterococcus coverage**
- Outpatient parenteral therapy option

**Doripenem**:
- Similar to meropenem
- Less commonly used

### Clinical Uses

- **Severe sepsis/septic shock** (empiric broad-spectrum)
- **Multi-drug resistant Gram-negatives** (ESBL-producing organisms)
- **Intra-abdominal infections** (severe)
- **Neutropenic fever** (if resistant organisms suspected)
- **HAP/VAP** (if MDR risk)
- **Meningitis** (meropenem preferred - lower seizure risk)

### Adverse Effects

- **Hypersensitivity**: Rash, anaphylaxis
  - **Cross-reactivity with penicillins**: ~50% (higher than cephalosporins)
- **Seizures**: Especially imipenem (high doses, renal impairment, CNS pathology)
- **GI upset, diarrhea**
- **C. difficile infection**
- **Promotes resistance**: Use judiciously (carbapenem-sparing strategies)

### Clinical Pearls

1. **Reserve for serious infections**: Avoid unnecessary use (promotes CRE)
2. **Meropenem for CNS infections**: Lower seizure risk
3. **Ertapenem for outpatient OPAT**: Once-daily, no Pseudomonas
4. **High cross-reactivity with penicillins**: Caution in penicillin-allergic patients

---

## Monobactams

### Aztreonam

**Unique Features**:
- **Only monobactam** in clinical use
- β-lactam structure (monocyclic)
- **NO cross-reactivity with other β-lactams** (safe in penicillin/cephalosporin allergy)

**Spectrum**:
- **Gram-negative ONLY**: Enterobacteriaceae, Pseudomonas
- **NO Gram-positive or anaerobic activity**

**Clinical Uses**:
- Gram-negative infections **in penicillin-allergic patients**
- Alternative to aminoglycosides (less nephrotoxicity)

**Adverse Effects**:
- Generally well tolerated
- No cross-allergenicity with other β-lactams

---

## Aminoglycosides

**Drugs**: Gentamicin, Tobramycin, Amikacin, Streptomycin, Neomycin

### Mechanism of Action

- Bind **30S ribosomal subunit**
- Inhibit protein synthesis
- Cause misreading of mRNA
- **Bactericidal**
- **Concentration-dependent killing** (higher peak → better kill)
- **Post-antibiotic effect** (PAE)

**Uptake**:
- Require **oxygen-dependent active transport** into bacteria
- **NOT effective against anaerobes** (lack O2-dependent transport)

### Spectrum

- **Gram-negative aerobes**: Enterobacteriaceae, Pseudomonas
- **Gram-positive**: Limited (Staphylococcus, Enterococcus - synergy with cell-wall agents)
- **NOT active**: Anaerobes, streptococci (alone)

### Pharmacokinetics

- **Polar, hydrophilic**: Poor oral absorption, poor CNS penetration
- **IV or IM** administration
- **Minimal protein binding**
- **Renal excretion** (100% unchanged)
- **Volume of distribution**: ~0.25 L/kg (extracellular fluid)
- **Not metabolized**

**Dosing**:
- **Once-daily dosing** preferred (concentration-dependent killing, PAE)
- Dose based on actual or adjusted body weight
- **Monitor**: Peak and trough levels (or trough alone for once-daily)

### Clinical Uses

1. **Gram-negative sepsis** (severe)
2. **Pseudomonas infections** (with β-lactam for synergy)
3. **Endocarditis** (with β-lactam for synergy vs. Streptococcus, Enterococcus)
4. **Tularemia** (streptomycin)
5. **Plague** (streptomycin, gentamicin)
6. **Tuberculosis** (streptomycin - second-line)
7. **Synergy**: With β-lactams for Enterococcus, Pseudomonas

### Adverse Effects

**Nephrotoxicity** (10-25%):
- **Mechanism**: Accumulation in proximal tubular cells → necrosis
- **Reversible** (usually)
- **Risk factors**: Duration >7 days, elderly, volume depletion, concomitant nephrotoxins
- **Monitoring**: SCr, BUN
- **Prevention**: Once-daily dosing, adequate hydration, monitor levels

**Ototoxicity** (3-14%):
- **Vestibular toxicity**: Vertigo, ataxia, nystagmus
- **Auditory toxicity**: Hearing loss (high-frequency first), tinnitus
- **Often irreversible**
- **Mechanism**: Damage to hair cells in inner ear
- **Risk factors**: Prolonged therapy, high trough levels, elderly, concomitant ototoxins (loop diuretics)
- **Monitoring**: Audiometry (baseline and periodic)

**Neuromuscular Blockade** (rare):
- Presynaptic and postsynaptic blockade
- Respiratory paralysis
- Risk: Myasthenia gravis, rapid IV infusion, concomitant neuromuscular blockers
- **Reversal**: Calcium gluconate

**Other**:
- Hypomagnesemia, hypocalcemia, hypokalemia

### Drug Interactions

- **Loop diuretics**: ↑Ototoxicity
- **Vancomycin**: ↑Nephrotoxicity
- **Amphotericin B**: ↑Nephrotoxicity
- **Neuromuscular blockers**: Prolonged paralysis

### Monitoring

**Therapeutic Drug Monitoring (TDM)** essential:
- **Traditional dosing** (TID):
  - Peak: 30 min after infusion (goal: Gentamicin 5-10 mcg/mL)
  - Trough: Just before next dose (goal: <2 mcg/mL)
- **Once-daily dosing**:
  - Trough before next dose (goal: <1 mcg/mL)
  - Or extended-interval nomograms

### Resistance

- **Enzymatic modification**: Acetyltransferases, phosphotransferases, adenylyltransferases
- **Amikacin**: Most resistant to enzymatic modification (broadest coverage)

### Clinical Pearls

1. **Once-daily dosing**: Preferred (better efficacy, less toxicity)
2. **Synergy with β-lactams**: Essential for Pseudomonas, Enterococcus endocarditis
3. **Not for monotherapy**: Usually combined with β-lactam
4. **Ineffective against anaerobes**: Require oxygen for uptake
5. **Monitor renal function and levels**: Prevent toxicity
6. **Limit duration**: Ideally <7 days

---

## Macrolides

**Drugs**: Erythromycin, Azithromycin, Clarithromycin, Fidaxomicin

### Mechanism of Action

- Bind **50S ribosomal subunit**
- Inhibit protein synthesis (translocation step)
- **Bacteriostatic** (bactericidal at high concentrations)

### Spectrum

- **Gram-positive**: Streptococci, MSSA (resistance increasing)
- **Atypical organisms**:
  - **Mycoplasma pneumoniae**
  - **Chlamydia pneumoniae, C. trachomatis**
  - **Legionella pneumophila**
- **Other**:
  - Bordetella pertussis (whooping cough)
  - Campylobacter
  - H. pylori (clarithromycin)

### Individual Agents

**Erythromycin**:
- **Prototype macrolide**
- **GI motility effects**: Motilin receptor agonist (pro-kinetic)
- **Clinical uses**:
  - Atypical pneumonia (rarely used now)
  - Pertussis
  - Gastroparesis (off-label)
- **Adverse effects**:
  - **GI intolerance** (nausea, vomiting, abdominal pain) - very common
  - QT prolongation, Torsades de pointes
  - Hepatotoxicity (cholestatic - erythromycin estolate)
- **Drug interactions**: Potent CYP3A4 inhibitor

**Azithromycin** (Zithromax, Z-pack):
- **Long half-life** (68 hours): Allows short courses (3-5 days)
- **Intracellular accumulation**: High tissue concentrations
- **Better tolerated** than erythromycin (less GI upset)
- **Clinical uses**:
  - **CAP** (atypical coverage)
  - **Chlamydia** (1 g × 1 dose)
  - **Gonorrhea** (with ceftriaxone)
  - **MAC prophylaxis** in HIV (CD4 <50)
  - **Pertussis**
- **Adverse effects**:
  - QT prolongation (less than erythromycin)
  - ↑Cardiovascular death (controversial, observational data)
  - Diarrhea
- **Drug interactions**: Minimal CYP inhibition (advantage)

**Clarithromycin** (Biaxin):
- **Better oral bioavailability** than erythromycin
- **Clinical uses**:
  - **H. pylori eradication** (triple/quadruple therapy)
  - **MAC treatment and prophylaxis** (HIV)
  - CAP (atypical coverage)
  - Sinusitis, bronchitis
- **Adverse effects**:
  - Metallic taste (common)
  - GI upset (less than erythromycin)
  - QT prolongation
- **Drug interactions**: CYP3A4 inhibitor

**Fidaxomicin** (Dificid):
- **Narrow-spectrum** macrolide
- **C. difficile infection**: Lower recurrence than vancomycin
- Minimal systemic absorption
- Very expensive

### Adverse Effects (Class)

- **GI intolerance**: Nausea, vomiting, diarrhea (erythromycin > clarithromycin > azithromycin)
- **QT prolongation**: Risk of Torsades de pointes
- **Hepatotoxicity**: Cholestatic jaundice (rare)
- **Ototoxicity**: High doses (reversible)

### Drug Interactions

**CYP3A4 Inhibition** (erythromycin, clarithromycin > azithromycin):
- ↑Levels of: Statins, warfarin, theophylline, carbamazepine, cyclosporine, tacrolimus
- **Avoid**: Simvastatin, lovastatin with erythromycin/clarithromycin (rhabdomyolysis)

### Resistance

- **Ribosomal methylation**: Erm genes (MLSB phenotype)
- **Efflux pumps**

### Clinical Pearls

1. **Azithromycin for atypicals**: First-line for CAP (with β-lactam)
2. **Z-pack compliance**: 5-day course improves adherence
3. **QT prolongation**: Monitor ECG in high-risk patients
4. **Clarithromycin for H. pylori**: Part of standard triple therapy
5. **Fidaxomicin for C. diff**: Lower recurrence but very expensive

---

## Fluoroquinolones

**Drugs**: Ciprofloxacin, Levofloxacin, Moxifloxacin, Delafloxacin

### Mechanism of Action

- Inhibit **DNA gyrase (topoisomerase II)** and **topoisomerase IV**
- Prevent DNA supercoiling and replication
- **Bactericidal**
- **Concentration-dependent killing**

### Spectrum

**Ciprofloxacin**:
- **Excellent Gram-negative**: Enterobacteriaceae, **Pseudomonas** (best anti-Pseudomonal quinolone)
- **Poor Gram-positive**: Streptococci, MRSA not covered
- Atypicals

**Levofloxacin** (Respiratory fluoroquinolone):
- Gram-negative (good but less anti-Pseudomonal than cipro)
- **Improved Gram-positive**: Streptococcus pneumoniae
- **Atypicals**: Mycoplasma, Legionella, Chlamydia

**Moxifloxacin** (Respiratory fluoroquinolone):
- Similar to levofloxacin
- **Anaerobic coverage** (unique among quinolones)
- **NO anti-Pseudomonal activity**

### Clinical Uses

**Ciprofloxacin**:
- **UTI** (complicated, pyelonephritis)
- **Pseudomonas infections**
- Intra-abdominal infections (with metronidazole)
- **Anthrax** (post-exposure prophylaxis)
- **Bacterial diarrhea**: Traveler's diarrhea, Shigella, Salmonella, Campylobacter

**Levofloxacin**:
- **CAP** (monotherapy or with β-lactam)
- HAP/VAP
- **UTI, pyelonephritis**
- Skin/soft tissue infections

**Moxifloxacin**:
- **CAP**
- Intra-abdominal infections (anaerobic coverage)
- **Tuberculosis** (second-line)

### Pharmacokinetics

- **Excellent oral bioavailability** (~100%)
- IV and PO nearly equivalent
- Broad tissue distribution (lungs, prostate, bone)
- **Renal excretion** (ciprofloxacin, levofloxacin) - dose adjust
- **Hepatic metabolism** (moxifloxacin) - no renal dose adjustment

### Adverse Effects

**Common**:
- **GI upset**: Nausea, diarrhea
- **CNS**: Headache, dizziness, insomnia

**Serious**:

**Tendon Rupture** (FDA Black Box Warning):
- **Achilles tendon** most common
- Risk factors: Age >60, corticosteroids, kidney transplant
- Can occur during or months after therapy
- **Discontinue immediately** if tendon pain

**QT Prolongation**:
- Risk of Torsades de pointes
- **Moxifloxacin > levofloxacin > ciprofloxacin**
- Avoid in patients with prolonged QT

**Peripheral Neuropathy**:
- Can be irreversible
- Discontinue if symptoms develop

**CNS Effects**:
- Seizures (especially in CNS disorders)
- Psychosis, confusion (elderly)
- Avoid in epilepsy

**Dysglycemia**:
- Hypo- or hyperglycemia (especially in diabetics)

**Aortic Aneurysm/Dissection**:
- Increased risk (recent FDA warning)
- Avoid in high-risk patients

**Phototoxicity**:
- Severe sunburn
- Use sunscreen

**C. difficile Infection**:
- Fluoroquinolones are major risk factor

### Drug Interactions

- **Multivalent cations** (Ca2+, Mg2+, Al3+, Fe2+):
  - Chelation → ↓absorption
  - Avoid antacids, dairy, iron, calcium supplements within 2-6 hours
- **QT-prolonging drugs**: Additive risk
- **Warfarin**: ↑INR (monitor)
- **NSAIDs**: ↑Seizure risk
- **Theophylline**: ↑Theophylline levels (ciprofloxacin)

### Resistance

- **Target mutations**: DNA gyrase, topoisomerase IV
- **Efflux pumps**
- **Widespread resistance**: E. coli, Pseudomonas (avoid empiric use for UTI in many areas)

### Contraindications

- Pregnancy (Category C, arthropathy in animals)
- Children <18 years (except specific indications like anthrax, CF with Pseudomonas)
- History of tendon disorders
- Myasthenia gravis (may worsen)

### Clinical Pearls

1. **Avoid for simple UTI**: Reserve due to resistance, adverse effects
2. **Ciprofloxacin for Pseudomonas**: Best oral option
3. **Respiratory quinolones**: Levofloxacin, moxifloxacin for CAP
4. **Black box warnings**: Tendon rupture, peripheral neuropathy, aortic issues
5. **Avoid with dairy/antacids**: Chelation decreases absorption
6. **C. diff risk**: Major risk factor
7. **Excellent bioavailability**: PO = IV

---

## Tetracyclines

**Drugs**: Tetracycline, Doxycycline, Minocycline, Tigecycline

### Mechanism of Action

- Bind **30S ribosomal subunit**
- Inhibit aminoacyl-tRNA binding
- Inhibit protein synthesis
- **Bacteriostatic**

### Spectrum

- **Broad-spectrum**:
  - Gram-positive (including MRSA for some)
  - Gram-negative
  - **Atypicals**: Mycoplasma, Chlamydia, Rickettsia
  - **Spirochetes**: Borrelia (Lyme), Treponema (syphilis - alternative)
  - Other: Vibrio cholerae, Brucella, Yersinia pestis

### Individual Agents

**Doxycycline**:
- **Most commonly used tetracycline**
- **Excellent oral bioavailability**
- **Long half-life**: BID dosing
- **Clinical uses**:
  - **CAP** (atypical coverage)
  - **Lyme disease** (early, localized)
  - **Rickettsioses**: Rocky Mountain spotted fever, ehrlichiosis, anaplasmosis
  - **Chlamydia**, **Mycoplasma**
  - **Acne vulgaris**
  - **Malaria prophylaxis**
  - **Anthrax** (post-exposure with cipro)
  - **Syphilis** (penicillin-allergic)
- **Advantages**: Renal dosing NOT required (hepatic/GI elimination)

**Minocycline**:
- Similar to doxycycline
- **MRSA coverage**
- **Clinical uses**:
  - Acne
  - MRSA skin infections (alternative)
- **Unique adverse effect**: Vestibular toxicity (dizziness, vertigo)

**Tigecycline** (Tygacil):
- **Glycylcycline** (tetracycline derivative)
- **Broad spectrum**:
  - MRSA, VRE
  - ESBL-producing Gram-negatives
  - Anaerobes
  - **NOT active against Pseudomonas or Proteus**
- **Clinical uses**:
  - Complicated skin/soft tissue infections
  - Intra-abdominal infections
  - **MDR organisms** (reserved use)
- **Black Box Warning**: ↑Mortality vs. other antibiotics (mechanism unclear)
- **Adverse effects**: Severe nausea/vomiting (common)

### Pharmacokinetics

- Oral absorption (take on empty stomach, except doxycycline/minocycline less affected by food)
- **Chelation with divalent/trivalent cations** (Ca2+, Mg2+, Fe2+, Al3+)
- Avoid: Dairy, antacids, iron within 2 hours
- **Doxycycline**: Hepatic/GI excretion (safe in renal failure)
- **Tetracycline**: Renal excretion (avoid in renal failure)

### Adverse Effects

**GI**:
- Nausea, vomiting, diarrhea
- Esophagitis (take with water, remain upright)

**Photosensitivity**:
- Severe sunburn
- Advise sunscreen, avoid excessive sun

**Teeth/Bone**:
- **Yellow-brown discoloration of teeth** (children <8 years)
- **Inhibits bone growth** (children)
- **Contraindicated in pregnancy and children <8 years**

**Hepatotoxicity**:
- Fatty liver (rare, high IV doses, pregnancy)

**Vestibular**:
- Minocycline: Dizziness, ataxia

**Intracranial Hypertension** (Pseudotumor Cerebri):
- Rare, especially minocycline

**Fanconi Syndrome**:
- Expired tetracycline (degradation products toxic to kidneys)
- **Never use expired tetracyclines**

### Contraindications

- **Pregnancy** (Category D): Affects fetal bone/teeth
- **Children <8 years**: Permanent tooth discoloration
- Severe hepatic impairment (tigecycline)

### Clinical Pearls

1. **Doxycycline for tick-borne diseases**: Rocky Mountain spotted fever, Lyme, ehrlichiosis
2. **Safe in renal failure**: Doxycycline, minocycline (not tetracycline)
3. **Avoid dairy, antacids**: Chelation decreases absorption
4. **Photosensitivity**: Warn patients about sun exposure
5. **Pregnancy/children**: Absolutely avoid
6. **Tigecycline for MDR**: Reserved for resistant organisms

---

## Glycopeptides

### Vancomycin

**Mechanism**:
- Inhibits cell wall synthesis
- Binds **D-Ala-D-Ala terminus** of peptidoglycan precursors
- Prevents transpeptidation and transglycosylation
- **Bactericidal** (time-dependent)

**Spectrum**:
- **Gram-positive ONLY** (large molecule, can't cross Gram-negative outer membrane)
- **MRSA** (drug of choice)
- **Coagulase-negative staphylococci**
- **Enterococcus** (E. faecalis, NOT VRE)
- **Streptococcus** (including penicillin-resistant S. pneumoniae)
- **C. difficile** (PO only, not absorbed)

**Pharmacokinetics**:
- **Poor oral absorption** (<10%)
- IV for systemic infections
- **Oral for C. diff** colitis (acts locally in colon)
- Renal excretion
- **Dose adjustment** in renal impairment

**Clinical Uses**:
- **MRSA infections** (bacteremia, endocarditis, pneumonia, osteomyelitis)
- **Empiric for serious Gram-positive infections** (until susceptibilities known)
- **Meningitis** (with ceftriaxone empirically)
- **C. difficile colitis** (PO vancomycin 125 mg QID)
- **Surgical prophylaxis** (β-lactam allergic, MRSA colonized)
- **Endocarditis prophylaxis** (β-lactam allergic)

**Dosing**:
- **IV**: 15-20 mg/kg q8-12h (loading dose 25-30 mg/kg may be used)
- **Oral** (C. diff): 125 mg QID
- **Target trough**: 10-20 mcg/mL (higher for serious infections like endocarditis, meningitis)

**Adverse Effects**:

**Red Man Syndrome**:
- Histamine release (non-allergic)
- Flushing, pruritus, rash on face, neck, upper torso
- Hypotension, tachycardia
- Due to **rapid infusion**
- **Prevention**: Infuse over ≥60 min, antihistamine premedication

**Nephrotoxicity**:
- Dose-related, reversible
- Risk factors: High trough (>20 mcg/mL), concomitant nephrotoxins, prolonged therapy
- Monitor: SCr, trough levels

**Ototoxicity**:
- Rare
- High troughs

**Thrombophlebitis**:
- IV site irritation

**Neutropenia**:
- Prolonged therapy (>2 weeks)

**Monitoring**:
- **Trough levels**: Before 4th or 5th dose
- **Renal function**: SCr
- **CBC**: If prolonged therapy

**Resistance**:
- **VRE**: Vancomycin-resistant enterococci (D-Ala-D-Ala → D-Ala-D-Lac)
- **VRSA**: Vancomycin-resistant S. aureus (rare)
- **VISA**: Vancomycin-intermediate S. aureus (MIC 4-8)

### Telavancin

- Lipoglycopeptide derivative
- **MRSA** skin infections, HAP/VAP
- Nephrotoxicity (monitor SCr)
- Teratogenic (pregnancy Category C → X equivalent)

---

## Other Important Antibiotics

### Linezolid (Zyvox)

**Class**: Oxazolidinone

**Mechanism**:
- Inhibits protein synthesis (binds 50S, prevents 70S initiation complex formation)
- **Unique mechanism** → no cross-resistance
- **Bacteriostatic** (Gram-positive); bactericidal (Streptococcus)

**Spectrum**:
- **Gram-positive ONLY**:
  - **MRSA**
  - **VRE** (including E. faecium)
  - Streptococci
  - Penicillin-resistant S. pneumoniae

**Clinical Uses**:
- **VRE** infections
- **MRSA** (alternative to vancomycin)
- **Pneumonia** (MRSA, VRE): Excellent lung penetration
- **Skin/soft tissue infections** (MRSA)

**Advantages**:
- **Excellent oral bioavailability** (~100%, PO = IV)
- Outpatient parenteral antibiotic therapy (OPAT) alternative
- CSF penetration

**Adverse Effects**:
- **Myelosuppression**: Thrombocytopenia, anemia (reversible, prolonged therapy >2 weeks)
  - Monitor CBC weekly
- **Peripheral neuropathy**: Prolonged use
- **Optic neuropathy**: Prolonged use (rare, irreversible)
- **Lactic acidosis**: Mitochondrial toxicity (prolonged use)
- **Serotonin syndrome**: MAOI activity (avoid SSRIs, SNRIs, meperidine, linezolid is weak MAOI)

**Monitoring**:
- CBC weekly (if >2 weeks therapy)
- Limit duration when possible (<28 days)

### Daptomycin (Cubicin)

**Mechanism**:
- **Lipopeptide**
- Inserts into bacterial cell membrane → depolarization → cell death
- **Bactericidal**
- **Concentration-dependent killing**

**Spectrum**:
- **Gram-positive ONLY**:
  - MRSA, MSSA
  - VRE
  - Streptococci
  - Coagulase-negative staphylococci

**Clinical Uses**:
- **MRSA bacteremia**
- **Endocarditis** (right-sided, S. aureus)
- **Complicated skin/soft tissue infections**
- **VRE** infections
- **NOT for pneumonia** (inactivated by pulmonary surfactant)

**Dosing**:
- 4-6 mg/kg IV daily (higher doses for bacteremia/endocarditis)

**Adverse Effects**:
- **CPK elevation, myopathy, rhabdomyolysis**:
  - Monitor CPK weekly
  - Hold if CPK >1000 or symptoms
- **Eosinophilic pneumonia** (rare)
- Peripheral neuropathy

**Contraindications**:
- **Pneumonia** (ineffective due to surfactant inactivation)

### Clindamycin

**Mechanism**:
- Binds 50S ribosomal subunit
- Inhibits protein synthesis
- **Bacteriostatic**

**Spectrum**:
- **Gram-positive**: MSSA, streptococci (NOT enterococci)
- **Anaerobes**: Bacteroides fragilis, Clostridium (NOT C. diff)
- **Atypicals**: Toxoplasma

**Clinical Uses**:
- **Anaerobic infections**: Aspiration pneumonia, intra-abdominal, pelvic
- **MSSA skin infections**
- **Streptococcal toxic shock syndrome** (inhibits toxin production)
- **Bacterial vaginosis** (metronidazole alternative)
- **Toxoplasmosis** (with pyrimethamine in sulfa-allergic)
- **PCP prophylaxis** (with primaquine, sulfa-allergic)

**Adverse Effects**:
- **C. difficile colitis**: High risk (disrupts gut flora)
- GI upset
- Rash

---

## Sulfonamides and Trimethoprim

### Trimethoprim-Sulfamethoxazole (TMP-SMX, Bactrim)

**Mechanism**:
- **Sequential blockade of folate synthesis**
- **Sulfa**: Inhibits dihydropteroate synthase (PABA → dihydrofolate)
- **Trimethoprim**: Inhibits dihydrofolate reductase (dihydrofolate → tetrahydrofolate)
- **Synergistic bactericidal effect**

**Spectrum**:
- **Broad**: Gram-positive and Gram-negative
- **MRSA** (community-acquired)
- **Stenotrophomonas maltophilia** (drug of choice)
- **Pneumocystis jirovecii** (PCP)
- Listeria, Nocardia, Toxoplasma

**Clinical Uses**:
- **UTI** (uncomplicated, complicated) - resistance increasing
- **MRSA** skin infections (community-acquired)
- **PCP** (treatment and prophylaxis in HIV)
- **Stenotrophomonas** infections
- **Nocardiosis**
- **Toxoplasmosis** (with pyrimethamine)
- **Listeria** (alternative)

**Adverse Effects**:
- **Hypersensitivity**: Rash (common), Stevens-Johnson syndrome (rare)
- **Hyperkalemia**: Trimethoprim (acts like K+-sparing diuretic)
- **Bone marrow suppression**: Especially with high doses, prolonged therapy
- **Crystalluria**: High doses, ensure hydration
- **Kernicterus**: Displaces bilirubin in neonates (avoid in pregnancy near term)
- **GI upset**: Nausea

**Contraindications**:
- Sulfa allergy
- Pregnancy (especially 1st trimester: folate antagonism; 3rd trimester: kernicterus)
- G6PD deficiency (hemolysis)

**Drug Interactions**:
- **Warfarin**: ↑INR
- **Methotrexate**: ↑Toxicity (both inhibit dihydrofolate reductase)

### Clinical Pearls

1. **MRSA**: Excellent oral option for community-acquired MRSA
2. **PCP**: Drug of choice for treatment and prophylaxis
3. **Monitor K+**: Trimethoprim causes hyperkalemia
4. **Sulfa allergy**: Common contraindication
5. **Resistance**: E. coli resistance increasing for UTI

---

## Key Takeaways - Antibiotics

1. **β-lactams**: Inhibit cell wall synthesis, time-dependent killing
2. **Penicillins**: Narrow to broad spectrum based on generation/modifications
3. **Cephalosporins**: ↑Generation → ↑Gram-negative coverage
4. **Carbapenems**: Broadest spectrum, reserve for serious/MDR infections
5. **Aminoglycosides**: Concentration-dependent, nephro/ototoxic, monitor levels
6. **Macrolides**: Atypical coverage, azithromycin most commonly used
7. **Fluoroquinolones**: Broad-spectrum, multiple black box warnings
8. **Tetracyclines**: Avoid pregnancy/children, doxycycline for tick-borne diseases
9. **Vancomycin**: MRSA drug of choice, monitor troughs, red man syndrome
10. **Antimicrobial stewardship**: Use narrowest spectrum, limit duration, prevent resistance

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. Sanford Guide to Antimicrobial Therapy, 2024
4. Gilbert DN, et al. The Sanford Guide to Antimicrobial Therapy. Antimicrobial Therapy Inc., 2024.
5. IDSA Guidelines on various infectious diseases
6. CDC Guidelines for Prevention of Healthcare-Associated Infections
